BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ANI Pharmaceuticals, Inc. Appoints Arthur S. Przybyl as Chief Executive Officer


3/10/2009 7:52:11 AM

WOODLAWN, Md.--(BUSINESS WIRE)--ANI Pharmaceuticals today announced the appointment of Arthur S. Przybyl, an experienced pharmaceutical industry executive, as the Company's new Chief Executive Officer. Mr. Przybyl's career includes several management positions in both pharmaceutical and medical device companies over the last twenty-five years. Most recently, Mr. Przybyl was the President and Chief Executive Officer of Akorn, Inc (NASDAQ:AKRX - News); a publicly traded pharmaceutical company focused on manufacturing and marketing sterile specialty pharmaceutical products. Mr. Przybyl transitioned Akorn, which he joined in 2002, from development stage to profitability, established a network of global business and product development partnerships, founded the company's vaccine division, and is widely respected for his business, operational and regulatory accomplishments. Mr. Przybyl will also become a member of ANI's Board of Directors.

Mr. Przybyl is replacing Tom Anderson, ANI's founding CEO, who is leaving to pursue other opportunities. Mr. Anderson will remain on ANI's Board of Directors.

Charlotte Arnold, a member of ANI's Board of Directors and representative of lead investor MVP Capital Partners, stated “On behalf of the Board and ANI’s investors, I am very pleased to welcome Art as the Company’s new Chief Executive Officer. I look forward to working with him and the entire ANI team to accomplish the company’s objective of becoming a leading specialty pharmaceutical company in the generic industry.”

Arthur S. Przybyl, ANI's CEO stated, “I am excited to join ANI Pharmaceuticals. I look forward to effectively working with and leading the management team and our employees to build upon ANI's existing successes and positive momentum. ANI has an opportunity to become a leading liquid specialty pharmaceutical company. I expect to execute the strategic vision already in place for ANI and to discover and grow new business opportunities as well.”

ANI Pharmaceuticals is a private specialty generic pharmaceutical company headquartered in Woodlawn, MD. ANI markets and manufactures liquid and oral solid prescription and over-the-counter pharmaceutical products and provides contract manufacturing services for other pharmaceutical companies. ANI owns and operates three manufacturing facilities located in Gulfport, Mississippi and Baudette, Minnesota.

Contact:

ANI Pharmaceuticals Regina Whelan Todd, 410-281-9450

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES